Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

Bayer's acquisition of Perfuse Therapeutics signifies a strategic move to strengthen its position in the ophthalmology market, potentially accelerating the development of innovative eye treatments. This deal highlights ongoing industry consolidation and investment in specialized healthcare solutions, benefiting consumers through advanced therapies. It also underscores the growing importance of targeted biotech acquisitions in shaping future medical advancements.

• Bayer aims to enhance its ophthalmology portfolio with this acquisition.
• The deal underscores industry consolidation in the biotech sector.
• Investments like this drive innovation in eye disease treatments.